{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:02:33Z","timestamp":1785420153066,"version":"3.56.0"},"reference-count":28,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01qat3289","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Next-generation sequencing (NGS) and the initiation of biomarker-driven first-line (1L) treatment on overall survival (OS) was evaluated in advanced\/metastatic non-small-cell lung cancer (a\/mNSCLC). By applying a time-dependent regression modeling approach accounting for fluidity of clinical care, this study aimed to capture the dynamic interplay between NGS testing, turnaround time (TaT), treatment decisions and timing of initiation, and outcomes more comprehensively than traditional static analyses. Methods: This study was a retrospective observational study using the US Flatiron Health EHR-derived de-identified database. Eligible adults had non-squamous a\/mNSCLC and received blood-based (B-NGS) or tissue-based (T-NGS) NGS within 90 days of diagnosis (1 January 2018\u201330 June 2023). A time-dependent covariate captured the NGS TaT, presence of a targetable alteration, time to 1L initiation, and 1L regimen (targeted concordant vs. discordant). OS was measured from the NGS order date to death. Results: A total of 1806 patients underwent B-NGS and 2583 underwent T-NGS. Starting empiric discordant 1L therapy before NGS results was associated with higher mortality versus initiating targeted concordant therapy after biomarker identification: B-NGS hazard ratio (HR): 1.58 (95% CI, 1.10\u20132.26); T-NGS HR: 1.07 (0.82\u20131.39). Considering discordant 1L therapy irrespective of timing, mortality remained higher versus targeted concordant therapy: B-NGS HR: 1.35 (1.04\u20131.74); T-NGS HR: 1.24 (0.98\u20131.56). Conclusions: This study demonstrates that waiting for comprehensive molecular profiling results before starting 1L treatment enables the delivery of appropriate biomarker-driven therapy, which translates into improved patient outcomes. Delays in NGS result availability or treatment initiation were linked to worse survival, underscoring the need for streamlined diagnostic workflows and rapid testing modalities.<\/jats:p>","DOI":"10.3390\/cancers18142287","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:08:34Z","timestamp":1784189314000},"page":"2287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Waiting Game: How NGS and Guideline-Concordant-Care Timing Shape Survival in Advanced NSCLC"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-3583","authenticated-orcid":false,"given":"Melina E.","family":"Marmarelis","sequence":"first","affiliation":[{"name":"Perelman Center for Advanced Medicine, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne M.","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, NC 27560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Marquart","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Whipple","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Allen-Coyle","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8021","authenticated-orcid":false,"given":"Naleen Raj","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Perelman Center for Advanced Medicine, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2025, July 01). Adenocarcinoma of the Lung and Bronchus SEER Relative Survival Rates by Time Since Diagnosis, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html."},{"key":"ref_2","unstructured":"National Cancer Institute (2025, July 17). Targeted Therapy Approved for Lung Cancer, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/approved-drug-list#targeted-therapy-approved-for-lung-cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5306\/wjco.v13.i4.276","article-title":"New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2","volume":"13","author":"Olmedo","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.1200\/JCO.2024.42.16_suppl.8640","article-title":"Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC)","volume":"42","author":"Subbiah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (2025, July 01). FDA Grants Accelerated Approval to Zenocutuzumab-Zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.6004\/jnccn.2023.7039","article-title":"Biomarker Testing, Treatment, and Outcomes in Patients With Advanced\/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database","volume":"21","author":"Bhandari","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e64399","DOI":"10.2196\/64399","article-title":"Next-Generation Sequencing\u2013Based Testing Among Patients With Advanced or Metastatic Nonsquamous Non\u2013Small Cell Lung Cancer in the United States: Predictive Modeling Using Machine Learning Methods","volume":"11","author":"Brnabic","year":"2025","journal-title":"JMIR Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Swaminathan, A., Stergiopoulos, S., Snider, J., Fisher, V., Castellanos, E., Snow, T., Cho-Phan, C., Comment, L., Cunningham, R., and McCusker, M. (2021). Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC). American Association for Cancer Research Annual Meeting, American Association for Cancer Research (AACR).","DOI":"10.1158\/1538-7445.AM2021-864"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9117","DOI":"10.1200\/JCO.2023.41.16_suppl.9117","article-title":"Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non\u2013small-cell lung cancer (aNSCLC) in the United States","volume":"41","author":"Levy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2300191","DOI":"10.1200\/PO.23.00191","article-title":"Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"7","author":"Aggarwal","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_12","first-page":"665","article-title":"Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer","volume":"22","author":"Nadhamuni","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/OP.22.00611","article-title":"Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data","volume":"20","author":"Scott","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes","volume":"340","author":"Hanley","year":"2010","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ijrobp.2011.10.025","article-title":"Immortal time bias: A frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy","volume":"83","author":"Park","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1073274818789355","DOI":"10.1177\/1073274818789355","article-title":"Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database","volume":"25","author":"Agarwal","year":"2018","journal-title":"Cancer Control"},{"key":"ref_18","first-page":"2053","article-title":"Modeling Survival Data: Extending the Cox Model","volume":"Volume 20","author":"Therneau","year":"2001","journal-title":"Statistics in Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12561-016-9157-9","article-title":"Understanding Landmarking and Its Relation with Time-Dependent Cox Regression","volume":"9","author":"Putter","year":"2017","journal-title":"Stat. Biosci."},{"key":"ref_20","first-page":"1521","article-title":"Immortal-time bias in older vs younger age groups: A simulation study with application to a population-based cohort of patients with colon cancer","volume":"128","author":"Pilleron","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2019.07.056","article-title":"Immortal Time Bias in National Cancer Database Studies","volume":"106","author":"Newman","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","unstructured":"Health, F. (2025, July 15). Database Characterization Guide. Published 18 March 2025. Available online: https:\/\/flatiron.com\/database-characterization."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput. Stat. Data Anal."},{"key":"ref_24","unstructured":"Williams, B., Mandrekar, J., Mandrekar, S., Cha, S., and Furth, A. (2006). Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes, Mayo Foundation."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/curroncol31030115","article-title":"Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre","volume":"31","author":"Fleming","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jtho.2023.12.009","article-title":"CD74\/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations","volume":"19","author":"Li","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s40001-025-03831-6","article-title":"Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis","volume":"31","author":"Fan","year":"2026","journal-title":"Eur. J. Med. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:18:13Z","timestamp":1784348293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":28,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142287"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142287","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}